Glaxo abandons sale of its older drugs portfolio December 4, 2014 British pharma giant GlaxoSmith-Kline revealed late yesterday afternoon that it would not be going ahead with the sale of a portfolio of old drugs that had been valued at over $3bn (£1.9bn). Chief executive Sir Andrew Witty had talked up interest in the selection of off-patent treatments last summer, with several private equity firms believed [...]
How does GSK’s new Ebola vaccine work? US safety trials show immunity with no side effects November 27, 2014 GSK's Ebola vaccine could soon be used to protect people against the disease in west Africa, after trials in the US gave volunteers immunity to the deadly virus without causing any negative side effects. Some 20 healthy people were administered the vaccine in an early-stage clinical trial, and all developed antibodies within four weeks, [...]
Is there a cure for Ebola? GlaxoSmithKline sees success in first human vaccine trials November 26, 2014 The first Ebola vaccine to be tested on humans has shown promising results in early trials, GlaxoSmithKline (GSK) said last night. GSK said the vaccine, co-developed with the US National Institutes of Health, was “well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the US who received it”. The [...]
GSK to start Ebola vaccine trials in west Africa next month November 13, 2014 GSK says its Ebola vaccine will begin trials in west Africa next month. Safety clinical trials will take place in Mali at a treatment centre run by the charity Medicins Sans Frontieres (MSF), which has been at the forefront of tackling the virus since the epidemic started in December last year. It is hoped [...]
Is there a cure for Ebola? Inhaled vaccine could provide answer to injection worries of GSK, NewLink and Johnson & Johnson November 4, 2014 Could a newly-developed inhaled vaccine soon be used to stop the spread of Ebola between humans in west Africa? Developed by a team of researchers at a university in Texas, it has already been shown to provide long-term protection for non-human primates against the deadly virus. The formulation took seven years to create, and [...]
GlaxoSmithKline considers £17bn HIV wonder drugs split with Viiv Healthcare IPO October 22, 2014 Pharma giant GlaxoSmithKline (GSK) is considering floating its HIV drugs business in a move that would see Viiv Healthcare among the top 40 companies in the FTSE 100 with a market valuation of up to £17bn. Chief executive Andrew Witty told reporters yesterday: “In line with our commitment to identifying ways to realise shareholder value, [...]
FTSE rises after Glaxo sets out recovery plan – London Report October 22, 2014 BRITAIN’S top share index yesterday ended higher, with motor insurers advancing on news of an increase in car premiums and drugmaker GlaxoSmithKline rising after its results. The FTSE 100 finished 0.4 per cent higher at 6,399.73 points. It had fallen more than 10 per cent in four weeks before making a marginal recovery since late [...]
GSK healthcare spin-off ViiV could generate one of the biggest IPOs in history: Here are some of the most successful corporate spin-offs stories October 22, 2014 ViiV Healthcare could generate one of the biggest IPOs in history, if GSK decides to go ahead and make it a spin-off company. The pharmaceutical firm was created in 2009 as a joint venture between GSK and US firm Pfizer. It specialises in developing therapies for HIV and operates in 16 countries. With [...]
GSK share price up despite Ebola vaccine delay: Head of research says it will be “too late” for this epidemic October 17, 2014 GlaxoSmithKline (GSK) has revealed that its Ebola vaccine won't be ready in time to deal with the current epidemic in west Africa. The British pharmaceutical giant started developing the vaccine earlier this year, in conjunction with the US National Institutes of Health. It uses a single protein from the Ebola virus to set off [...]
GSK confirms RBS’ Sir Philip Hampton as new chairman September 25, 2014 GlaxoSmithKline (GSK) has confirmed that Royal Bank of Scotland (RBS) chairman Sir Philip Hampton has been appointed to lead its board. The pharmaceutical giant said this morning that Hampton will join as non-executive director on 1 January next year, assuming the role of chairman from Sir Christopher Gent from 1 September. Although RBS did not [...]